Laveeza Bhatti

Ombitasvir, Paritaprevir Co-dosed With Ritonavir, Dasabuvir, and Ribavirin for Hepatitis C in Patients Co-infected With HIV-1

Mark Sulkowski, Joseph J. Eron, David Wyles et al. · JAMA · 2015 · 305 citations · Full text

Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial

Chloe Orkin, Jean‐Michel Molina, Eugènia Negredo et al. · The Lancet HIV · 2017 · 96 citations

Protease Inhibitors, Treatment And Prevention, Pharmacology +9

Peginterferon alfa-2a Plus Ribavirin for HIV-HCV Genotype 1 Coinfected Patients: A Randomized International Trial

M. Rodríguez‐Torres, Jihad Slim, Laveeza Bhatti et al. · HIV Clinical Trials · 2012 · 65 citations · Full text

Upregulation by Retinoic Acid of Interleukin-2-Receptor mRNA in Human T Lymphocytes

Neil Sidell, Bieshia Chang, Laveeza Bhatti · Cellular Immunology · 1993 · 46 citations

Inflammation, Cytokine, Autoimmune Disease +13

Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1

Joseph J. Eron, Chloe Orkin, Douglas Cunningham et al. · Antiviral Research · 2019 · 36 citations · Full text